-   6E10 combined with local prophylaxis selected for Phase 3 pivotal trials, with a favorable safety profile and potential best-in-class product profile at 26 weeks -   Efficacy: 76% of 6E10 patients were injection free, with maintained visual acuity and fluid control -   Safety: 100% of 6E10 difluprednate-alone patients had no or minimal inflammation, and none received corticosteroids for treatment of inflammation beyond the scheduled prophylaxis -   Patient Preference Survey: 88% of patients indicated a ...